Necitumumab (Portrazza) - Oncology Nurse Advisor

Necitumumab (Portrazza)

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews necitumumab (Portrazza), indicated for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC), in combination with gemcitabine and cisplatin.

Next hm-slideshow in Slides